VDB News - Candlesense

PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint

What regulatory hurdles could arise if the company seeks to re‑file or modify the trial design? What short‑term trading strategies (e.g., options, short selling) are appropriate given the negative sentiment? How will analyst consensus and target price estimates be revised after this announcement?

Clinical trials

11 days ago